Compare Incyte Corporation (INCY) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.97. Which is the better fit depends on your goals.
| INCY | PDBC | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | — |
52-Week High | $129.93 | $18.91 |
52-Week Low | $81.61 | $12.90 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $17.97, up 0.79% today, with a strong bullish technical signal from moving averages. Recent news highlights institutional accumulation, with Geneos Wealth Management increasing its position by 150.6% in Q1 2026 (SEC filing, July 19, 2026), and commodities gaining attention as an inflation hedge amid Middle East tensions.
The ETF offers diversified commodity exposure without K-1 tax forms, but faces risks from commodity price volatility and geopolitical events. While technical momentum is positive, a Seeking Alpha report from June 11, 2026, downgraded PDBC to hold due to weakening commodity momentum, indicating cautious near-term outlook despite long-term inflation-hedging appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
